Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors

Drugs of Today

Volumn 39, Issue 3, 2003, Pages 157-173

  Di Cosimo, Serena ^a,c   Ferretti, Gianluigi ^b   Papaldo, Paola ^b   Carlini, Paolo ^b   Fabi, Alessandra ^b   Cognetti, Francesco ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDAZOLECARBOXYLIC ACID; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLUCOSE; INDAZOLE DERIVATIVE; LACTIC ACID; LONIDAMINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAMOXIFEN; UNCLASSIFIED DRUG; VINDESINE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BOLUS INJECTION; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PALLIATIVE THERAPY; CELL ENERGY; CELL METABOLISM; CLINICAL TRIAL; CYSTITIS; CYTOTOXICITY; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; ELECTRON TRANSPORT; ENERGY METABOLISM; FATIGUE; GASTROINTESTINAL DISEASE; GLYCOLYSIS; HEMATOLOGIC DISEASE; HUMAN; HYPERESTHESIA; LEUKOPENIA; LIVER METASTASIS; LUNG CANCER; MAJOR CLINICAL STUDY; MEMBRANE PERMEABILITY; METASTASIS; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; OXYGEN CONSUMPTION; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; PROSPECTIVE STUDY; REVIEW; SCROTAL PAIN; SOLID TUMOR; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0037368877     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.3.799451     Document Type: Review

References (48)

1. Paggi, M.G., Zupi, G., Fanciulli, M. et al. Effect of lonidamine on the utilization of 14C-labeled glucose by human astrocytoma cells. Exp Mol Pathol 1987, 47: 154-65.
2. Floridi, A., Delpino, A., Nista, A. et al. Effect of lonidamine on protein synthesis in neoplastic cells. Exp Mol Pathol 1985, 42: 293-305.
3. Costantini, P., Jacotot, E., Decaudin, D., Kroemer, G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000, 92: 1042-53.
4. Pulselli, R., Amadio, L., Fanciulli, M., Floridi, A. Effect of lonidamine on the mitochondrial potential in situ in Ehrlich ascites tumor cells. Anticancer Res 1996, 16: 419-23.
5. Belzacq, A.S., El Hamel, C., Vieira, H.L. et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001, 20: 7579-87.
6. Sordet, O., Rebe, C., Leroy, I. et al. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 2001, 97: 3931-40.
7. Ravagnan, L., Marzo, I., Costantini, P. et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999, 18: 2537-46.
8. Malorni, W., Meschini, S., Matarrese, P., Arancia, G. The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine. Anticancer Res 1992, 12: 2037-45.
9. Mardor, Y., Kaplan, O., Sterin, M. et al. Non-invasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy. Cancer Res 2000, 60: 5179-86.
10. Dell'Antone, P., Piergallini, L. The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. Biochim Biophys Acta 1997, 1358: 46-52.
11. Dell'Antone, P., Bragadin, M., Piergallini, L. Lonidamine cytotoxicity: Involvement of the lysosomal compartment. J Int Med Res 2000, 28: 269-76.
12. Ben-Yoseph, O., Lyons, J.C., Song, C.W., Ross, B.D. Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol 1998, 36: 149-57.
13. Floridi, A., Gambacurta, A., Bagnato, A. et al. Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp Mol Pathol 1988, 49: 421-31.
14. Floridi, A., Bianchi, C., Bagnato, A. et al. Lonidamine-induced outer membrane permeability and susceptibility of mitochondria to inhibition by adriamycin. Anticancer Res 1987, 7: 1149-52.
15. Bagnato, A., Bianchi, C., Caputo, A., Silvestrini, B., Floridi, A. Enhancing effect of lonidamine on the inhibition of mitochondrial respiration by adriamycin. Anticancer Res 1987, 7: 799-802.
16. Zupi, G., Molinari, A., D'Agnano, I. et al. Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Anticancer Res 1995, 15 (6B): 2469-77.
17. Fanciulli, M., Valentini, A., Bruno, T., Citro, G., Zupi, G., Floridi, A. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncol Res 1996, 8: 111-20.
18. Fanciulli, M., Bruno, T., Giovannelli, A. et al. Energy metabolism of human LoVo colon carcinoma cells: Correlation to drug resistance and influence of lonidamine. Clin Cancer Res 2000, 6: 1590-7.
19. Del Bufalo, D., Biroccio, A., Soddu, S. et al. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 1996, 98: 1165-73.
20. Biroccio, A., Del Bufalo, D., Fanciulli, M., Bruno, T., Zupi, G., Floridi, A. Bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Int J Cancer 1999, 82: 125-30.
21. Floridi, A., Bruno, T., Miccadei, S., Fanciulli, M., Federico, A., Paggi, M.G. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 1998, 56: 841-9.
22. Chekulayev, V., Shevchuk, I., Chekulayeva, L., Kahru, A.J. Study of the photochemical and phototoxic properties of lonidamine [1-(2, 4-dichlorobenzyl)-1H-indazol-3-carboxylic acid. Photochem Photobiol B 1997, 41: 11-21.
23. Sica, G., Lama, G., lacopino, F., Angelucci, C., Della Cuna, G.R., Marchetti, P. Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. Anticancer Res 1991, 11: 2099-102.
24. Gatzemeier, U., Toomes, H., Picollo, R., Christoffel, V., Lucker, P.W., Ulmer, J. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer. Arzneimittelforschung 1991, 41: 436-9.
25. Mansi, J.L., de Graeff, A., Newell, D.R. et al. A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer. Br J Cancer 1991, 64: 593-7.
26. Newell, D.R., Mansi, J., Hardy, J. et al. The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Semin Oncol 1991, 18 (Suppl. 4): 11-7.
27. Nistico, C., Garufi, C., Milella, M. et al. Weekly epirubicin plus lonidamine in advanced breast carcinoma. Breast Cancer Res Treat 1999, 56: 233-7.
28. Lopez, M., Vici, P., Di Lauro, L. et al. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. Eur J Cancer 1995, 31A: 1611-4.
29. Gebbia, V., Borsellino, N., Testa, A. et al. Cisplatin and epirubicin plus oral lonidamine as firstline treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs 1997, 8: 943-8.
30. Dogliotti, L., Danese, S., Berruti, A. et al. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: A pilot study. Cancer Chemother Pharmacol 1998, 41: 333-8.
31. Calabresi, F., Di Lauro, L., Marolla, P. et al. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: A multicentric randomized clinical study. Semin Oncol 1991, 18 (Suppl. 4): 66-72.
32. Amadori, D., Frassineti, G.L., De Matteis, A. et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial. Breast Cancer Res Treat 1998, 49: 209-17.
33. Pacini, P., Rinaldini, M., Algeri, R. et al. FEC (5fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomized study. Final results. Eur J Cancer 2000, 36: 966-75.
34. Dogliotti, L., Berruti, A., Buniva, T. et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. J Clin Oncol 1996, 14: 1165-72.
35. De Lena, M., Lorusso, V., Latorre, A. et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001, 37: 364-8.
36. De Lena, M., Lorusso, V., Bottalico, C. et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol 1997, 15: 3208-13.
37. Bottalico, C., Lorusso, V., Brandi, M. et al. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. Anticancer Res 1996, 16: 3865-9.
38. Gadducci, A., Brunetti, I., Muttini, M.P. et al. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 1994, 30A: 1432-5.
39. Contu, A., Olmeo, N.A., Pani, P., Deriu, A., Ortu, S., Paga, C. Lonidamine in non-small-cell lung cancer: A phase II study. Tumori 1991, 77: 52-5.
40. Comella, P., Frasci, G., Panza, N. et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999, 17: 1526-34.
41. Portalone, L., Lombardi, A., Antilli, A. et al. Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: A phase II study. Tumori 1999, 85: 239-42.
42. De Marinis, F., Rinaldi, M., Ardizzoni, A. et al. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: A phase III randomized FONICAP trial. Italian Lung Cancer Task Force. Tumori 1999, 85: 177-82.
43. Salvati, F., Antilli, A., Cruciani, A.R. et al. Lonidamine plus cyclophosphamide in the treatment of advanced non-small cell lung cancer in the elderly: A phase II study. Tumori 1995, 81: 48-51.
44. lanniello, G.P., De Cataldis, G., Comella, P. et al. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer 1996, 78: 63-9.
45. Gatzemeier, U., Cavalli, F., Haussinger, K. et al. Phase III trial with and without lonidamine in nonsmall cell lung cancer. Semin Oncol 1991, 18 (Suppl. 4): 42-8.
46. Scarantino, C.W., Newton, R.E., Paggiarino, D.A., DeGregorio, M. Lonidamine in head and neck cancer: An overview. Semin Oncol 1991, 18 (Suppl. 4): 28-32.
47. Stahl, M., Schmoll, E., Becker, H. et al. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: Results of an ongoing randomized phase II study. Semin Oncol 1991, 18 (Suppl. 4): 33-7.
48. Schiffer, D., Sales, S., Soffietti, R. Lonidamine in malignant brain tumors. Semin Oncol 1991, 18 (Suppl. 4): 38-41.